🔗 Share this article

An underground market for unlicensed slimming drugs is propelled by social media fitness personalities and sellers on communication apps, based on recent findings.

Investigational Treatment Gaining Popularity Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Followers are encouraged to message these accounts privately for supplier links, while also receiving discount codes.

Thriving Trade on Social Networks

Separately, a robust market exists on messaging services, where communities with numerous of members share comparison images, injection guides and claims of rapid UK delivery. Sellers market the substance there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

This medication is an investigational injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the next Ozempic.

Medical Experts Voice Concerns

However, physicians and pharmacists have warned that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals injecting products of unknown origin.

Some experts stated the demand for the experimental drug could be linked to the rising price of licensed weight loss treatments such as Mounjaro.

Regulatory Position and Implementation

Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, marketing, and customer regulations, potentially leading to penalties, legal action or imprisonment.

Service Reaction and Material Removal

Based on the social media company, the platform has taken down problematic material and banned associated keywords and query recommendations. The organization said it was committed to maintaining the service safe and allocating resources in strengthening compliance measures.

Online Trading Operations

Research also discovered communities with up to nine thousand participants selling retatrutide using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” immediately brings up channels with thousands of users, filled with photos of weight loss, positive reviews and detailed guides for mixing or injecting at home.

Within minutes of entering one community, a seller shared WhatsApp details, where most transactions occur. The seller sent an guidebook and promised delivery within 48 hours. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None inquired about body mass, health issues or previous experience.

Product Information and Costs

Inside these groups, messages display dark colored packages with Royal Mail labels, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with sterile water, or pre-filled injectors typically priced at £160 for 20 milligrams. When asked how much time a injector should last, vendors give contradictory responses ranging from a several days to “depends on your body”.

Service Moderation and Safety Measures

A representative for the messaging service stated it regularly moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering materials they cannot confirm. Although the science behind this drug is valid, these online versions may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the surge in interest to recent cost increases for approved slimming medications such as Mounjaro. “With prices increasing, patients are using social media. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she explained.

Her staff has already seen patients harmed by self-injection from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly said the substance was in third stage clinical trials and had not been reviewed or authorized by any government authority globally. “Therefore at this point no one can sell [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to potentially serious health risks”.